Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study
- PMID: 20542295
- DOI: 10.1016/j.jpeds.2010.04.066
Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study
Abstract
Objectives: To evaluate the beneficial effects of Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation.
Study design: A double-blind, placebo-controlled, randomized study was conducted from January 2008 to December 2008 in 44 consecutive infants at least 6 months old (mean age+/-SD, 8.2+/-2.4 SD; male/female, 24/20) admitted to the Gastrointestinal Endoscopy and Motility Unit of the Department of Pediatrics, University "Federico II" of Naples, with a diagnosis of functional chronic constipation. The 44 infants with chronic constipation were randomly assigned to 2 groups: group A (n=22) received supplementation with the probiotic L reuteri (DSM 17938) and group B (n=22) received an identical placebo. Primary outcome measures were frequency of bowel movements per week, stool consistency, and presence of inconsolable crying episodes, recorded in a daily diary by parents.
Results: Infants receiving L reuteri (DSM 17938) had a significantly higher frequency of bowel movements than infants receiving a placebo at week 2 (P=.042), week 4 (P=.008), and week 8 (P=.027) of supplementation. In the L reuteri group, the stool consistency was reported as hard in 19 infants (86.4%) at baseline, in 11 infants (50%) at week 2, and in 4 infants (18.2%) at weeks 4 and 8. However, there was no significant difference between L reuteri and placebo groups in the stool consistency at all weeks (P=.63, week 2; P=.38, week 4; P=.48, week 8). Similarly, there was no statistically difference in the 2 groups in the presence of inconsolable crying episodes. No adverse effects were reported.
Conclusions: The administration of L reuteri (DSM 17938) in infants with chronic constipation had a positive effect on bowel frequency, even when there was no improvement in stool consistency and episodes of inconsolable crying episodes. Because of their safety profile, probiotics may be an attractive option in the treatment of functional constipation.
Copyright (c) 2010 Mosby, Inc. All rights reserved.
Similar articles
-
The role of a probiotics mixture in the treatment of childhood constipation: a pilot study.Nutr J. 2007 Aug 4;6:17. doi: 10.1186/1475-2891-6-17. Nutr J. 2007. PMID: 17683583 Free PMC article.
-
The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial.J Gastrointestin Liver Dis. 2014 Dec;23(4):387-91. doi: 10.15403/jgld.2014.1121.234.elr. J Gastrointestin Liver Dis. 2014. PMID: 25531996 Clinical Trial.
-
Effect of Lactobacillus reuteri NCIMB 30351 drops on symptoms of infantile functional gastrointestinal disorders and gut microbiota in early infants: Results from a randomized, placebo-controlled clinical trial.Eur J Pediatr. 2024 May;183(5):2311-2324. doi: 10.1007/s00431-024-05473-y. Epub 2024 Mar 1. Eur J Pediatr. 2024. PMID: 38427038 Clinical Trial.
-
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.Eur Urol. 2004 Apr;45(4):420-9; discussion 429. doi: 10.1016/j.eururo.2004.01.008. Eur Urol. 2004. PMID: 15041104 Review.
-
Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis.Pediatrics. 2018 Jan;141(1):e20171811. doi: 10.1542/peds.2017-1811. Pediatrics. 2018. PMID: 29279326 Review.
Cited by
-
Limosilactobacillus reuteri promotes the expression and secretion of enteroendocrine- and enterocyte-derived hormones.bioRxiv [Preprint]. 2024 Aug 31:2024.08.30.610555. doi: 10.1101/2024.08.30.610555. bioRxiv. 2024. PMID: 39257733 Free PMC article. Preprint.
-
Probiotics in Functional Gastrointestinal Disorders.Adv Exp Med Biol. 2024;1449:157-174. doi: 10.1007/978-3-031-58572-2_10. Adv Exp Med Biol. 2024. PMID: 39060737 Review.
-
[Research status and prospects of probiotics in functional gastrointestinal disorders in infants and toddlers].Zhongguo Dang Dai Er Ke Za Zhi. 2024 May 15;26(5):529-534. doi: 10.7499/j.issn.1008-8830.2401141. Zhongguo Dang Dai Er Ke Za Zhi. 2024. PMID: 38802916 Free PMC article. Review. Chinese.
-
Probiotic formulations and gastro-intestinal diseases in the paediatric population: a narrative review.Ann Med Surg (Lond). 2024 Apr 4;86(5):2836-2847. doi: 10.1097/MS9.0000000000002007. eCollection 2024 May. Ann Med Surg (Lond). 2024. PMID: 38694362 Free PMC article. Review.
-
Unraveling the complexity of Disorders of the Gut-Brain Interaction: the gut microbiota connection in children.Front Pediatr. 2024 Feb 16;11:1283389. doi: 10.3389/fped.2023.1283389. eCollection 2023. Front Pediatr. 2024. PMID: 38433954 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
